H World Group Limited American Depositary Shares vs Novo Nordisk A/S — how do they compare? H World Group Limited American Depositary Shares trades at $44.16 (market cap $13.25B), while Novo Nordisk A/S trades at $38.52 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 12.5× H World Group Limited American Depositary Shares's market cap, and H World Group Limited American Depositary Shares pays the higher dividend (5.08%). Which is the better fit depends on your goals — on Pluang, investors hold H World Group Limited American Depositary Shares for 0 Days and Novo Nordisk A/S for 116 Days on average.
| HTHT | NVO | |
|---|---|---|
Market Cap | $13.25B | $165.31B |
Volume | 1,177,261 | 11,432,838 |
Sector | Consumer Cyclical | Health |
52-Week High | $56.06 | $63.98 |
52-Week Low | $36.99 | $35.29 |
Typical Hold Time | 0 Days | 116 Days |
Enterprise Value | $16.03B | $179.56B |
Dividend Yield | 5.08% | 4.71% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Novo Nordisk (NVO) trades at $38.26, up 1.95% today, with a bullish technical signal supported by oscillators like RSI at 20.06 (buy signal). The company shows strong fundamentals with a P/E of 9.66, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights pipeline developments, including a Wegovy pill study showing continued weight loss and a $4 billion licensing deal, though an FDA delay for a hemophilia drug poses a near-term headwind.
The outlook remains positive with a consensus price target of $44.67, implying 17% upside, driven by robust profitability and growth in GLP-1 therapies. Risks include competitive pressure from Eli Lilly, regulatory delays, and reliance on obesity/diabetes drugs. Analyst sentiment is bullish (59% buy ratings), but investors should monitor execution amid high expectations.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
H World Group operates hotels through leased and owned, managed franchise, and franchise models. Its brands include HanTing, JI Hotel, Orange Hotel, and Steigenberger Hotels & Resorts.
Read more on HTHT →With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →